These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

352 related articles for article (PubMed ID: 32591986)

  • 1. Factors influencing adherence to adjuvant endocrine therapy in breast cancer-treated women: using real-world data to inform a switch from acute to chronic disease management.
    Cavazza M; Banks H; Ercolanoni M; Cukaj G; Bianchi G; Capri G; Longo F
    Breast Cancer Res Treat; 2020 Aug; 183(1):189-199. PubMed ID: 32591986
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association Between Out-Of-Pocket Costs, Race/Ethnicity, and Adjuvant Endocrine Therapy Adherence Among Medicare Patients With Breast Cancer.
    Farias AJ; Du XL
    J Clin Oncol; 2017 Jan; 35(1):86-95. PubMed ID: 28034069
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adherence trajectories of adjuvant endocrine therapy in the five years after its initiation among women with non-metastatic breast cancer: a cohort study using administrative databases.
    Lambert-Côté L; Bouhnik AD; Bendiane MK; Bérenger C; Mondor M; Huiart L; Lauzier S
    Breast Cancer Res Treat; 2020 Apr; 180(3):777-790. PubMed ID: 32086655
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adjuvant therapy use among Appalachian breast cancer survivors.
    Tan X; Marshall VD; Anderson RT; Donohoe J; Camacho F; Balkrishnan R
    Medicine (Baltimore); 2015 Jul; 94(26):e1071. PubMed ID: 26131828
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ethnic differences in initiation and timing of adjuvant endocrine therapy among older women with hormone receptor-positive breast cancer enrolled in Medicare Part D.
    Farias AJ; Du XL
    Med Oncol; 2016 Feb; 33(2):19. PubMed ID: 26786154
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Race and Patient-reported Symptoms in Adherence to Adjuvant Endocrine Therapy: A Report from the Women's Hormonal Initiation and Persistence Study.
    Sheppard VB; Sutton AL; Hurtado-de-Mendoza A; He J; Dahman B; Edmonds MC; Hackney MH; Tadesse MG
    Cancer Epidemiol Biomarkers Prev; 2021 Apr; 30(4):699-709. PubMed ID: 33514603
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Are breast cancer patients with suboptimal adherence to cardiovascular treatment more likely to discontinue adjuvant endocrine therapy? Competing risk survival analysis in a nationwide cohort of postmenopausal women.
    Artignan J; Capmas P; Panjo H; Constantinou P; Pelletier-Fleury N
    BMC Med; 2023 Nov; 21(1):463. PubMed ID: 38001491
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Factors associated with endocrine therapy adherence among post-menopausal women treated for early-stage breast cancer in Ontario, Canada.
    Blanchette PS; Lam M; Richard L; Allen B; Shariff SZ; Vandenberg T; Pritchard KI; Chan KKW; Louie AV; Desautels D; Raphael J; Earle CC
    Breast Cancer Res Treat; 2020 Jan; 179(1):217-227. PubMed ID: 31571072
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Factors Associated with Adherence to Adjuvant Endocrine Therapy Among Privately Insured and Newly Diagnosed Breast Cancer Patients: A Quantile Regression Analysis.
    Farias AJ; Hansen RN; Zeliadt SB; Ornelas IJ; Li CI; Thompson B
    J Manag Care Spec Pharm; 2016 Aug; 22(8):969-78. PubMed ID: 27459660
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Five-Year Adjuvant Endocrine Therapy Adherence Trajectories Among Women With Breast Cancer: A Nationwide French Study Using Administrative Data.
    Lailler G; Memoli V; Le Bihan Benjamin C; Ben Diane MK; Lauzier S; Mancini J; Bousquet PJ; Bouhnik AD
    Clin Breast Cancer; 2021 Aug; 21(4):e415-e426. PubMed ID: 33745868
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Statin use and breast cancer recurrence in postmenopausal women treated with adjuvant aromatase inhibitors: a Danish population-based cohort study.
    Harborg S; Heide-Jørgensen U; Ahern TP; Ewertz M; Cronin-Fenton D; Borgquist S
    Breast Cancer Res Treat; 2020 Aug; 183(1):153-160. PubMed ID: 32572715
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Testing a behavioral intervention to improve adherence to adjuvant endocrine therapy (AET).
    Shelby RA; Dorfman CS; Bosworth HB; Keefe F; Sutton L; Owen L; Corsino L; Erkanli A; Reed SD; Arthur SS; Somers T; Barrett N; Huettel S; Gonzalez JM; Kimmick G
    Contemp Clin Trials; 2019 Jan; 76():120-131. PubMed ID: 30472215
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Personal and clinical social support and adherence to adjuvant endocrine therapy among hormone receptor-positive breast cancer patients in an integrated health care system.
    Kroenke CH; Hershman DL; Gomez SL; Adams SR; Eldridge EH; Kwan ML; Ergas IJ; Kubo A; Kushi LH
    Breast Cancer Res Treat; 2018 Aug; 170(3):623-631. PubMed ID: 29671113
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Association of Endocrine Therapy Initiation Timeliness With Adherence and Continuation in Low-Income Women With Breast Cancer.
    Sood N; Liu Y; Lian M; Greever-Rice T; Lucht J; Schmaltz C; Colditz GA
    JAMA Netw Open; 2022 Aug; 5(8):e2225345. PubMed ID: 35921108
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Efficacy of adjuvant endocrine therapy in breast cancer patients with a positive-to-negative switch of hormone receptor status after neoadjuvant chemotherapy].
    Xia G; Zhu J; Yuan J; Cao B; Tang J; Chen Y
    Zhejiang Da Xue Xue Bao Yi Xue Ban; 2016 May; 45(6):614-619. PubMed ID: 28247605
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical factors associated with patterns of endocrine therapy adherence in premenopausal breast cancer patients.
    Woolpert KM; Schmidt JA; Ahern TP; Hjorth CF; Farkas DK; Ejlertsen B; Collin LJ; Lash TL; Cronin-Fenton DP
    Breast Cancer Res; 2024 Apr; 26(1):59. PubMed ID: 38589932
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adherence and discontinuation of adjuvant hormonal therapy in breast cancer patients: a population-based study.
    Wigertz A; Ahlgren J; Holmqvist M; Fornander T; Adolfsson J; Lindman H; Bergkvist L; Lambe M
    Breast Cancer Res Treat; 2012 May; 133(1):367-73. PubMed ID: 22286315
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Racial Differences in Patient-Reported Symptoms and Adherence to Adjuvant Endocrine Therapy Among Women With Early-Stage, Hormone Receptor-Positive Breast Cancer.
    Hu X; Walker MS; Stepanski E; Kaplan CM; Martin MY; Vidal GA; Schwartzberg LS; Graetz I
    JAMA Netw Open; 2022 Aug; 5(8):e2225485. PubMed ID: 35947386
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Factors associated with intentional and unintentional non-adherence to adjuvant endocrine therapy following breast cancer.
    Brett J; Fenlon D; Boulton M; Hulbert-Williams NJ; Walter FM; Donnelly P; Lavery B; Morgan A; Morris C; Watson E
    Eur J Cancer Care (Engl); 2018 Jan; 27(1):. PubMed ID: 27901302
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of patient race and geographical factors on initiation and adherence to adjuvant endocrine therapy in medicare breast cancer survivors.
    Camacho FT; Tan X; Alcalá HE; Shah S; Anderson RT; Balkrishnan R
    Medicine (Baltimore); 2017 Jun; 96(24):e7147. PubMed ID: 28614244
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.